Search SAMHSA Publications and Digital Products
Store Facets Summary
- Clear all filters
- Remove Family & Advocates
- Remove Parents & Caregivers
- Remove Prevention Professionals
- Remove Substance Abuse
- Remove People with Substance Use or Abuse Problems as Population Group
- Remove Treatment Improvement
- Remove TIP Series - Treatment Improvement Protocols (TIPS)
- Remove Treatment
- Remove Naltrexone
Main page content
Published: August 2021
The Executive Summary of this Treatment Improvement Protocol provides an overview on the use of the three Food and Drug Administration-approved medications used to treat opioid use disorder—methadone, naltrexone, and buprenorphine—and the other strategies and services needed to support recovery.
Published: July 2021
This Treatment Improvement Protocol (TIP) reviews the use of the three Food and Drug Administration (FDA)-approved medications used to treat OUD—methadone, naltrexone, and buprenorphine—and the other strategies and services needed to support recovery for people with OUD. This is a revision.
Published: January 2008
This document gives primary care clinicians specific guidance on identifying indications of substance abuse, how to broach the subject with a patient, and what screening and assessment instruments to use. It explains how to perform an office-based brief intervention in which patient and clinician set mutually agreed-upon goals and "contract" to stop or cut back the alcohol or other drug use.